Nurnberg, Germany

Ingomar Grafe



Average Co-Inventor Count = 2.6

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Nurnberg, DE (1998 - 2000)
  • Nürnberg, DE (2001)

Company Filing History:


Years Active: 1998-2001

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: Ingomar Grafe: Innovator in Pharmaceutical Chemistry

Introduction

Ingomar Grafe is a notable inventor based in Nurnberg, Germany, recognized for his contributions to pharmaceutical chemistry. He holds a total of seven patents, showcasing his innovative approach to developing stable pharmaceutical compounds.

Latest Patents

Grafe's latest patents include advancements in thermally stable trimetrexates and processes for producing them. His invention provides thermally stable forms of 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline, or trimetrexate. This includes a crystalline monohydrate form that offers increased stability over the anhydrous variant. Additionally, he has developed a new crystalline and anhydrous form of doxazosin mesylate, characterized by specific reflex positions in its X-ray spectrum. This new form presents significant advantages in synthesis and pharmaceutical processing.

Career Highlights

Throughout his career, Grafe has worked with reputable companies such as Heumann Pharma GmbH and U.S. Bioscience, Inc. His work has significantly impacted the field of pharmaceutical development, particularly in creating stable compounds for medical use.

Collaborations

Grafe has collaborated with notable professionals in the industry, including Johann Peter Morsdorf and Martin Stogniew. These collaborations have contributed to the advancement of his research and innovations.

Conclusion

Ingomar Grafe's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in drug stability and formulation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…